After attending this symposium, participants will be able to:
1. Evaluate emerging clinical, translational, and health systems research findings presented across Sutter Health and describe their potential impact on patient care, population health, and healthcare delivery. ​

2. Identify evidence-based research methods, innovations, and best practices that can be applied to advance research quality, scholarly productivity, and clinical effectiveness within their own practice or operational setting.

​3. Recognize opportunities for interdisciplinary collaboration and knowledge dissemination that support the translation of research findings into meaningful improvements in clinical outcomes, healthcare operations, and organizational strategy across Sutter Health.

​Presentation: Proteomic Disorder in the Blood Predicts Unplanned Hospitalization and Functional Decline in Older Adults: Findings from the SOMMA Cohort
- Identify the practice gap existing for identifying older adults at risk and the importance of filling it
- Compare the association between proteomic disorder and both physical function and unplanned hospitalization, including the size of the risk after adjustment (HR 1.85).
- Identify the patient groups that might benefit from a biological aging measure

Presentation: Finding the Polyps We Used to Miss: How Sutter Data Linked Physician Detection Quality to Later Colorectal Cancer Risk
- Differentiate the sessile serrated lesion detection rate from the adenoma detection rate and explain why the two measures capture different aspects of colonoscopy quality.
- Interpret the observed association between physician SSLDR and patients’ subsequent risk of post colonoscopy colorectal cancer, including the adjusted risk difference between the highest and lowest detection quartiles.
- Identify at least two potential health-system applications of SSLDR, such as complementary quality measurement, physician feedback, coaching, or targeted detection training.

Presentation: Effectiveness of a Lung Nodule and Cancer Screening Program in Improving Lung Cancer Detection, Early-Stage Diagnosis, and Mortality
- Describe gaps in adherence to lung cancer screening guidelines and care coordination that may limit effective screening, follow-up, and early detection among high-risk patients.
- Identify eligible patients and appropriately refer them to a comprehensive, navigator-supported Lung Nodule & Cancer Screening Program to facilitate timely follow-up after abnormal LDCT screening results.
- Evaluate the impact of the LNCSP on cancer detection rates, stage at diagnosis, mortality, and health equity outcomes.
- Identify system-level strategies to improve guideline adherence, optimize resource utilization, and enhance multidisciplinary care coordination for high-risk patients undergoing lung cancer screening.
- Apply lessons learned to strengthen lung cancer screening implementation and follow-up processes within their own practice settings.

Presentation: PREDICT TRIAL - precision medicine to stratify de-escalation therapy in breast cancer treatment
- Explain the core principle of precision medicine — that patients whose disease looks identical by traditional clinical and pathologic features can differ biologically, and that molecular testing can sort them into groups who will or won't benefit from a given treatment, allowing therapy to be matched to the individual rather than the average patient.
- Describe the limitations of clinicopathologic criteria (age, grade, size, RTOG 9804-like eligibility) for selecting which women with DCIS treated by breast-conserving surgery benefit from adjuvant radiation, in the context of a century of evidence-based de-escalation from radical mastectomy through breast conserving surgery. 
- Recognize how biomarker-guided care supports de-escalation and "first, do no harm" — using biologic information to safely withhold treatment from patients unlikely to benefit, sparing them its burdens and toxicities, while ensuring those who do benefit still receive it, and appreciate how such tools inform shared decision-making between clinician and patient.

Presentation: Bicycle and Motorized Micromobility Trauma Have Distinct Injury Patterns and Hospital Utilization 
- Compare the demographic characteristics and injury patterns of patients presenting with traditional bicycle-related trauma versus motorized micromobility-related trauma. - Analyze differences in hospital resource utilization and clinical outcomes between traditional bicycle and motorized micromobility trauma populations.
- Evaluate the relative likelihood of head, chest, and spine injuries among patients injured while using traditional bicycles compared with motorized micromobility devices.

Presentation: Next-generation precision medicine at scale: How multiomics profiling in the Sutter Health Biobank supports the development of novel diagnostics for diagnosis and treatment. 
- Analyze the role of comprehensive genomic testing in supporting personalized patient care and disease prevention strategies.
- Differentiate the applications of pharmacogenetics, clinical genetics, and proteomics in predicting, preventing, and detecting disease. 
- Evaluate how genomic and proteomic data can be used to inform individualized treatment plans and improve patient outcomes.